Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Nuvo Pharmaceuticals Inc NRIFF


Primary Symbol: MRVFF

Healthcare Drug Manufacturers - Specialty & Generic
Nuvo Pharmaceuticals Inc is a Canadian focused healthcare company doing business as Miravo Healthcare with global reach and a diversified portfolio of commercial products. Its product targets several therapeutic areas, including pain, allergy, and dermatology. The company's strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets.


OTCQX:MRVFF - Post by User

Nuvo Pharmaceuticals Inc
Bullboard Posts
User Avatar Image
(0)
•••
Comment by paljoeyon Oct 22, 2014 7:44pm
396 Views
Post# 23052663

RE:RE:RE:Hard Asset value of $8 per share

RE:RE:RE:Hard Asset value of $8 per shareWhat's there not to like about management?
They took over a bankrupt company 10 years ago.
They now have 4 drugs approved by FDA , 5 drugs in Phase 11 clinical trials, a dozen more in preclinical , over 200 patents, a brilliant litigation against Maloincroft, monetization of Pennsaid and an advanced drug in WF10 that offers multi billions in sales and a balance sheet that has over $60 million in cash and all debt paid off.

No hype or aggressive promotional fluff and all business.
And they have skin in the game.

Nuvo is shaping up to be a great canadian success story.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities